News

Press Releases

September 23, 2020

OncoImmune, Inc. announced today that it has dosed the first patient in the first-in-human clinical trial of ONC-392, its novel, […]

Read more
December 30, 2019

OncoImmune, Inc. announced today that its Investigational New Drug (“IND”) application for ONC-392, its novel, next generation anti-CTLA-4 antibody, has […]

Read more
Scroll to Top